|
|
|
03.06.25 - 23:51
|
XFRA: DIVIDEND/INTEREST INFORMATION - 05.06.2025 - EQUBF_01 (XETRA)
|
|
|
Das Instrument 87N IT0005452658 STEVANATO GROUP SPA O.N. EQUITY wird cum Dividende/Zinsen gehandelt am 04.06.2025 und ex Dividende/Zinsen am 05.06.2025
The instrument 87N IT0005452658 STEVANATO GROUP SPA O.N. EQUITY has its pre-dividend/interest day on 04.06.2025 and its ex-dividend/interest day on 05.06.2025...
|
|
|
|
|
|
|
08.05.25 - 12:42
|
Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025 (Business Wire)
|
|
|
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025.
First Quarter 2025 Highlights (comparisons to prior-year period)
Revenue for the first quarter of 2025 increased 9% to €256.6 million, and high-value solutions represented 43% of total revenue.
Gross profit margin increased 80 basis points to 27.2%.
Diluted earnings per share were €0.10, and adjusted diluted earnings per share were €0.10.
Adjusted EBITDA margin increased 100 basis points to 22.4%.
The Company is maintaining its fiscal 2025 revenue guidance of €1,160 million to €1,190 million, and is updating its guidance for adjusted EBITDA and adjusted diluted earnings per share to reflect the expected impact from tariffs. As a result, the Company now expects adjusted EBITDA in the range of €288.5 ...
|
|
|
|
|
24.04.25 - 23:18
|
Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
|
|
|
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2025 on Thursday, May 8, 2025, at 6:30 a.m. (ET).
Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 8, 2025, to discuss financial results. During the call, management will refer to a slide presentation, which will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website.
Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: STVN conference call pre-registra...
|
|
|
|
|
|
|
|
|
06.03.25 - 12:33
|
Stevanato Group Reports Record Revenue of €1,104 Million for Fiscal Year 2024 (Business Wire)
|
|
|
- Introduces 2025 Guidance -
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and fiscal year 2024.
Fourth Quarter and Full-Year 2024 Highlights (comparisons to prior-year period)
Revenue for the fourth quarter of 2024 increased 3% to €330.6 million, and high-value solutions represented 40% of total revenue, in line with Company expectations.
For the fourth quarter, diluted earnings per share were €0.18, and adjusted diluted earnings per share were €0.19.
Adjusted EBITDA margin increased 50 basis points to 27.5% for the fourth quarter.
For fiscal year 2024, revenue increased 2% to €1,104 million, and high-value solutions represented 38% of total revenue.
For fiscal year 2024, diluted earnings per share were €0.43, and adjusted diluted earnings per share wer...
|
|
|
24.02.25 - 22:03
|
Stevanato Group to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 6, 2025 (Business Wire)
|
|
|
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2024 on Thursday, March 6, 2025, at 6:30 a.m.(ET).
Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation that will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website.
Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants are encouraged to pre-register for the conference call using the following link: STVN conference c...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
